(Reuters) - A group of lawmakers is calling on the National Institutes of Health and Department of Health and Human Services to step in and reduce the cost of Medivation Inc's and Astellas Pharma Inc's prostate cancer drug Xtandi.
http://ift.tt/22WbsvW
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire